Phase 1 Clinical Trial of Ipilimumab In Pediatric Patients With Advanced Solid Tumors

PURPOSE: Ipilimumab is a first-in-class immune checkpoint inhibitor approved for treatment of metastatic melanoma but not studied in children until this phase 1 protocol. EXPERIMENTAL DESIGN: This study examined safety, pharmacokinetics, and immunogenicity, and immune correlates of ipilimumab admini...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Cancer Res
Auteurs principaux: Merchant, Melinda S., Wright, Matthew, Baird, Kristin, Wexler, Leonard H., Rodriguez-Galindo, Carlos, Bernstein, Donna, Delbrook, Cindy, Lodish, Maya, Bishop, Rachel, Wolchok, Jedd D., Streicher, Howard, Mackall, Crystal L.
Format: Artigo
Langue:Inglês
Publié: 2015
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5027962/
https://ncbi.nlm.nih.gov/pubmed/26534966
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-0491
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires